GSC
PSTV

Ground Swell Capital’s Plus Therapeutics PSTV Stock Holding History

Ground Swell Capital’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-458
Closed -$3.98K – 212
2025
Q2 		$3.98K Sell
458
-88
-16% -$1.15K 0.01% 138
2025
Q1 		$13K Buy
+546
New +$15.3K 0.03% 136
2024
Q1 		– Sell
-572
Closed -$25.6K – 112
2023
Q4 		$25.6K Buy
+572
New +$22.9K 0.09% 46
2014
Q3 		– Hold
0
– -$1K – 2689
2014
Q2 		– Hold
0
– – – 1765

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Ground Swell Capital's PSTV Position: Q3 2025 in Review

Ground Swell Capital sold out of Plus Therapeutics (PSTV) in Q3 2025, closing a stake of 458 shares — an estimated $3.98K sold.

Ground Swell Capital first reported a position in PSTV in Q4 2023 and held it in 3 quarters. The position peaked at $25.6K in Q4 2023. 20 funds tracked by Wall St. Rank hold PSTV as of Q3 2025.

  • Ground Swell Capital reported no remaining Plus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 458 Plus Therapeutics shares in Q3 2025, an estimated $3.98K.
  • Ground Swell Capital first reported a position in Plus Therapeutics in Q4 2023 and held it in 3 quarters.
  • Ground Swell Capital's Plus Therapeutics position peaked at $25.6K in Q4 2023.
  • 20 funds tracked by Wall St. Rank held Plus Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.